11/22
04:09 pm
nby
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 [Yahoo! Finance]
Low
Report
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024 [Yahoo! Finance]
11/22
04:05 pm
nby
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
Low
Report
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
11/17
03:02 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/15
08:04 am
nby
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand [Yahoo! Finance]
Low
Report
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand [Yahoo! Finance]
11/15
08:00 am
nby
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
Low
Report
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
11/11
01:23 pm
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) had its price target lowered by analysts at Ascendiant Capital Markets from $8.00 to $0.85. They now have a "buy" rating on the stock.
Low
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) had its price target lowered by analysts at Ascendiant Capital Markets from $8.00 to $0.85. They now have a "buy" rating on the stock.
11/9
02:07 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/7
04:05 pm
nby
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
Low
Report
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
11/6
05:06 pm
nby
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price [Yahoo! Finance]
Medium
Report
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price [Yahoo! Finance]
11/6
04:05 pm
nby
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
High
Report
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
11/1
02:04 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/29
08:00 am
nby
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
Low
Report
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
9/30
02:04 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
9/23
01:11 pm
nby
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, NBY, ARC on Behalf of Shareholders
Medium
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, NBY, ARC on Behalf of Shareholders
9/23
09:27 am
nby
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm
Medium
Report
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm
9/22
02:02 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
9/20
09:21 am
nby
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders
High
Report
NBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.’s Avenova Brand and Business Is Fair to Shareholders
9/20
08:30 am
nby
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
High
Report
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
9/20
08:00 am
nby
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
High
Report
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
9/14
02:07 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
9/6
02:06 am
nby
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
9/2
06:07 am
nby
Impetigo Drugs Global Strategic Business Report 2024 - Fusidane Drug Segment is Expected to Reach US$883.5 Million by 2030, with a CAGR of a 5.1% [Yahoo! Finance]
Medium
Report
Impetigo Drugs Global Strategic Business Report 2024 - Fusidane Drug Segment is Expected to Reach US$883.5 Million by 2030, with a CAGR of a 5.1% [Yahoo! Finance]